Luc F. Van Gaal - Concepedia

Author

Luc F. Van Gaal

Also Known As

L F Van Gaal, L. F. Van Gaal, L. F. van Gaal, L.F. VAN GAAL, L.F. Van Gaal, Luc F Van Gaal, Luc F. Van Gaal, Luc F. van Gaal, Van Gaal, Luc F.

216

Publications

18.9K

Citations

H-Index

Concepts

All Affiliations

Antwerp University Hospital University of Antwerp University College London Jessa Hospital University of Liège

About

Luc F. Van Gaal is an author at Antwerp University Hospital specializing in medicine, metabolic syndrome, and obesity.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	26	45	4.9K
2	Health Sciences	18	26	3.3K
3	Public Health	10	10	382
4	Allergy	1	1	65
5	Biochemistry	1	1	62

Luc F. Van Gaal

Publications

13.3K

Citations

H-Index

Page 1

	Year	Citations
Once-Weekly Semaglutide in Adults with Overweight or Obesity John Wilding, Rachel L. Batterham, Salvatore Calanna, New England Journal of Medicine	2021	3.9K
Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study Luc F. Van Gaal, Aila Rissanen, André Scheen, The Lancet ObesityMetabolic SyndromeCannabis UseCardiovascular DiseaseHealth Policy	2005	1.5K
Effect of Sibutramine on Cardiovascular Outcomes in Overweight and Obese Subjects W. P. T. James, Ian D. Caterson, Walmir Coutinho, New England Journal of Medicine	2010	924
Effect of sibutramine on weight maintenance after weight loss: a randomised trial W. P. T. James, Arne Astrup, Nick Finer, The Lancet ObesityNutritionWeight LossWeight MaintenanceRandomised Trial	2000	817
Exenatide versus Insulin Glargine in Patients with Suboptimally Controlled Type 2 Diabetes Robert J. Heine, Luc F. Van Gaal, Don Johns, Annals of Internal Medicine	2005	794
Weight regain and cardiometabolic effects after withdrawal of semaglutide: The <scp>STEP</scp> 1 trial extension John Wilding, Rachel L. Batterham, Melanie J. Davies, Diabetes Obesity and Metabolism	2022	766
Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study André Scheen, Nick Finer, Priscilla Hollander, The Lancet ObesityMetabolic SyndromeDiabetes ManagementInsulin ManagementDiabetes	2006	735
The beneficial effects of modest weight loss on cardiovascular risk factors. Luc F. Van Gaal, M. Wauters, Ivo H. De Leeuw PubMed	1997	308
Among inflammation and coagulation markers, PAI-1 is a true component of the metabolic syndrome Ilse Mertens, An Verrijken, Jan Michiels, International Journal of Obesity InflammationMetabolic SyndromeCoagulation MarkersAutoimmune DiseaseMetabolic Disorder	2006	174
Long-term effect of CB1 blockade with rimonabant on cardiometabolic risk factors: two year results from the RIO-Europe Study † Luc F. Van Gaal, André Scheen, Aila Rissanen, European Heart Journal	2008	156

Page 1